Optimizing rosacea treatment outcomes isn’t only about papules and pustules. Facial erythema needs to be part of an effective management plan.
In this presentation on rosacea from Maui Derm NP+PA Fall 2021, Julie Harper, MD, explains why combination therapy is more effective and how classifying rosacea patients by subtype can lead to suboptimal treatments.
Hilary Baldwin, MD, presented on how to recognize, diagnose, and treat rosacea in patients with skin of color at the Skin of Color Update 2021.
The National Rosacea Society has recently released recommendations based on a group discussion regarding updates in rosacea.
Challenges with overlaps in diagnosis and classification based on rosacea’s 4 subtypes are creating a new focus on features of the condition in each patient. A pipeline of new drugs awaiting FDA approvals could further expand options.
Novel inhibitor of the 26S proteasome was found to be safe, well-tolerated, and effective in reducing inflammatory lesions and erythema in patients with rosacea.
Camp Wonder, a camp that supports kids with skin disease and is sponsored by Galderma, is celebrating their 20th year of operations this week.
Journey Medical Corporation and Dr. Reddy’s Laboratories Ltd. have joined forces for the development and commercialization of DFD-19 as a treatment for rosacea.
Dermoscopy cannot diagnose D folliculorum proliferation but can reveal specific findings in patients with papulopustular rosacea.